Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Significant Growth in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 145,800 shares, an increase of 43.4% from the August 15th total of 101,700 shares. Based on an average daily trading volume, of 1,889,300 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

Several analysts have recently weighed in on BAYRY shares. The Goldman Sachs Group started coverage on Bayer Aktiengesellschaft in a report on Thursday, May 30th. They set a “neutral” rating on the stock. Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating and nine have issued a hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Bayer Aktiengesellschaft Trading Up 0.7 %

Shares of BAYRY stock opened at $7.51 on Monday. The stock’s fifty day moving average is $7.46 and its 200-day moving average is $7.42. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. Bayer Aktiengesellschaft has a 52 week low of $6.82 and a 52 week high of $13.29.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.25. The business had revenue of $12 billion for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. As a group, sell-side analysts forecast that Bayer Aktiengesellschaft will post 1.38 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.